Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
| Autor: | A. E. Nikitin, E. E. Averin, D. E. Rozhkov, A. V. Sozykin, G. A. Procenko |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Рациональная фармакотерапия в кардиологии, Vol 16, Iss 1, Pp 33-39 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1819-6446 2225-3653 |
| DOI: | 10.20996/1819-6446-2020-02-06 |
| Popis: | Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (aged of 61.53±1.14 years; 31 [63.3%] men) receiving alirocumab who did not reach the target low density lipoprotein cholesterol (LDL-C) concentrations despite the ongoing optimal lipid-lowering therapy. In all patients, the initial level of lipids was evaluated, as well as their parameters after subsequent alirocumab injections.Results. LDL-C serum level significantly decreased after the first injection compared to the initial level from 2.92±0.22 to 1.65±0.19 mmol/L (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|